Additional Data From Multiple Phase 1 and 2 Studies of S*BIO's Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)

Wednesday, June 1, 2011 General News
Email Print This Page Comment
Font : A-A+

--SB1518 Alleviates MF-Associated Splenomegaly and Shows No Myelosuppression and No Exacerbation of Cytopenias-

S*BIO Pte Ltd:

Russo Partners

Hew Yin Chin, Ph.D.

Tony Russo +1 212-845-4251

Associate Director, Corporate Development

Tony.Russo@russopartnersllc.com

Tel: +65 6827 5000 (Singapore)

Andreas Marathovouniotis +1 212-845-4235

yinchin_hew@sbio.com

Andreas.Marathis@russopartnersllc.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook